- Healthcare Professionals
- OncoLink Scientific Meetings Coverage
Radiation Therapy With Concurrent Weekly Carboplatin and Paclitaxol in Advanced Stage Unresectable Squamous Cell Carcinoma of the Head and Neck
James Metz, MD
OncoLink Associate Editor
Last Modified: November 1, 1999
Presenter: Michael L. Haas, MD
Affiliation: University of Maryland
Advanced squamous cell carcinoma of the head and neck region generally has a poor outcome with radiation therapy alone. This study was designed to evaluate concurrent chemoradiation therapy for the treatment of unresectable head and neck cancer.
From 1993-1998 62 patients received weekly carboplatin/taxol chemotherapy with radiation therapy. Radiation was delivered to a total dose of 70.2 Gy in 1.8 Gy fractions to the primary site. The majority of patients had oropharyngeal cancer.
- The complete response rate was 82% at the primary site and 63% in the neck nodes.
- Overall, 75% had no clinical evidence of residual disease at the completion of therapy.
- With a median follow-up of 30 months, the overall survival at 3 years was 48%.
- The local control rate at 3 years was 63%.
The results of this Phase II study of concurrent chemoradiation are very encouraging for a disease that is notoriously difficult to control. Confirmation of this experience will require Phase III trials.
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.